Marker Therapeutics, Inc. - Common Stock (MRKR)

1.3200
+0.4668 (54.71%)
NASDAQ · Last Trade: Nov 19th, 11:33 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.8532
Open1.020
Bid1.290
Ask1.310
Day's Range0.9842 - 1.680
52 Week Range0.8101 - 2.460
Volume36,085,342
Market Cap11.78M
PE Ratio (TTM)-3.771
EPS (TTM)-0.4
Dividend & YieldN/A (N/A)
1 Month Average Volume1,681,718

Chart

About Marker Therapeutics, Inc. - Common Stock (MRKR)

Marker Therapeutics Inc is a biopharmaceutical company focused on the development of innovative immunotherapy treatments for cancer. The company specializes in creating personalized T cell therapies designed to harness the body's immune system to target and eliminate tumors. By utilizing a unique approach that enhances T cell functionality, Marker Therapeutics aims to provide more effective treatment options for various types of malignancies, contributing to advancements in oncology and improving patient outcomes through precision medicine. Read More

News & Press Releases

US Top Movers for Nov. 19, 2026: Gainers and Loserschartmill.com
Via Chartmill · November 19, 2026
US Top Stock Movers: VIVS Gains 79.17%, PIIIW Falls 75.56% in Today's Sessionchartmill.com
Via Chartmill · November 19, 2026
Gap Stocks on November 19, 2026: Vivid Seats and NewGenIvf Lead Moverschartmill.com
Via Chartmill · November 19, 2026
Premarket Small-Cap Movers: Nov. 19, 2026 Gainers and Loserschartmill.com
Via Chartmill · November 19, 2026
Marker Therapeutics Stock Drops After Report About Lymphoma Treatmentbenzinga.com
Marker Therapeutics reports strong safety and efficacy data for MT-601 in lymphoma patients, with durable responses and no serious adverse events.
Via Benzinga · August 26, 2025
Tuesday's pre-market session: top gainers and loserschartmill.com
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Via Chartmill · August 26, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · July 17, 2025
Here are the top movers in Thursday's session.chartmill.com
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · July 17, 2025
Gapping stocks in Thursday's sessionchartmill.com
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · July 17, 2025
Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earningsbenzinga.com
Via Benzinga · July 17, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 17, 2025
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 14, 2025
Which stocks have an unusual volume on Monday?chartmill.com
Which stocks have an unusual volume on Monday?
Via Chartmill · March 10, 2025
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga.com
Via Benzinga · March 5, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 19, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 5, 2024
MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024investorplace.com
MRKR stock results show that Marker Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 14, 2024
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023investorplace.com
Marker Therapeutics just reported results for the fourth quarter of 2023.
Via InvestorPlace · June 28, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 5, 2024
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024investorplace.com
Marker Therapeutics just reported results for the first quarter of 2024.
Via InvestorPlace · May 15, 2024
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritizationbenzinga.com
Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. 
Via Benzinga · January 8, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · December 29, 2023
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · December 11, 2023
Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 12/11
Marker Therapeutics, Inc. (NASDAQ: MRKR) is one of today’s top gainers. The company’s shares have moved 1.92% on the day to $2.65.
Via Investor Brand Network · December 11, 2023
Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?benzinga.com
Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter 
Via Benzinga · September 11, 2023